Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 14, 2019; 25(30): 4222-4234
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4222
Published online Aug 14, 2019. doi: 10.3748/wjg.v25.i30.4222
Figure 2 Transforming growth factor-beta 1 inhibits bone morphogenetic protein 7 in a time- and dose-dependent manner.
A: Western blot analysis of expression of BMP7. Primary mouse HSCs were serum starved for 20 h, treated with TGF-β1 at the indicated dose (ng/mL) for 24 h, and lysed. Equivalent amount of whole cell detergent lysates were blotted with the indicated antibodies for detecting BMP7 and GAPDH. B: Densitometry analysis of BMP7 at the indicated TGF-β1 dose. C: Western blot analysis of expression of BMP7 and α-SMA. Primary mouse HSCs were serum starved for 20 h, treated with TGF-β1 (2 ng/mL) for the indicated time periods (h), and lysed. Equivalent amount of whole cell detergent lysates were blotted with the indicated antibodies. D: Densitometry analysis of the association of BMP7 and α-SMA at the indicated time in response to TGF-β1 stimulation. Data are pooled from at least three independent experiments and represented as the mean ± SE. cP < 0.01 or dP < 0.01 compared to time point 0. BMP7: Bone morphogenetic protein 7; TGF-β: Transforming growth factor-beta; α-SMA: Alpha-smooth muscle actin.
- Citation: Zou GL, Zuo S, Lu S, Hu RH, Lu YY, Yang J, Deng KS, Wu YT, Mu M, Zhu JJ, Zeng JZ, Zhang BF, Wu X, Zhao XK, Li HY. Bone morphogenetic protein-7 represses hepatic stellate cell activation and liver fibrosis via regulation of TGF-β/Smad signaling pathway. World J Gastroenterol 2019; 25(30): 4222-4234
- URL: https://www.wjgnet.com/1007-9327/full/v25/i30/4222.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i30.4222